Literature DB >> 18511292

Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.

Suhendan Ekmekcioglu1, John B Mumm, Malini Udtha, Sunil Chada, Elizabeth A Grimm.   

Abstract

Restoration of the tumor-suppression function by gene transfer of the melanoma differentiation-associated gene 7 (MDA7)/interleukin 24 (IL-24) successfully induces apoptosis in melanoma tumors in vivo. To address the molecular mechanisms involved, we previously revealed that MDA7/IL-24 treatment of melanoma cells down-regulates interferon regulatory factor (IRF)-1 expression and concomitantly up-regulates IRF-2 expression, which competes with the activity of IRF-1 and reverses the induction of IRF-1-regulated inducible nitric oxide synthase (iNOS). Interferons (IFNs) influence melanoma cell survival by modulating apoptosis. A class I IFN (IFN-alpha) has been approved for the treatment of advanced melanoma with some limited success. A class II IFN (IFN-gamma), on the other hand, supports melanoma cell survival, possibly through constitutive activation of iNOS expression. We therefore conducted this study to explore the molecular pathways of MDA7/IL-24 regulation of apoptosis via the intracellular induction of IFNs in melanoma. We hypothesized that the restoration of the MDA7/IL-24 axis leads to upregulation of class I IFNs and induction of the apoptotic cascade. We found that MDA7/IL-24 induces the secretion of endogenous IFN-beta, another class I IFN, leading to the arrest of melanoma cell growth and apoptosis. We also identified a series of apoptotic markers that play a role in this pathway, including the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas-FasL. In summary, we described a novel pathway of MDA7/IL-24 regulation of apoptosis in melanoma tumors via endogenous IFN-beta induction followed by IRF regulation and TRAIL/FasL system activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511292      PMCID: PMC2582834          DOI: 10.1016/j.cyto.2008.04.010

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  37 in total

Review 1.  Interferon regulatory factors: the next generation.

Authors:  Y Mamane; C Heylbroeck; P Génin; M Algarté; M J Servant; C LePage; C DeLuca; H Kwon; R Lin; J Hiscott
Journal:  Gene       Date:  1999-09-03       Impact factor: 3.688

2.  The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.

Authors:  L Zhao; A Dong; J Gu; Z Liu; Y Zhang; W Zhang; Y Wang; L He; C Qian; Q Qian; X Liu
Journal:  Cancer Gene Ther       Date:  2006-06-23       Impact factor: 5.987

Review 3.  Death receptors: signaling and modulation.

Authors:  A Ashkenazi; V M Dixit
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.

Authors:  Began Gopalan; Anya Litvak; Sikha Sharma; Abner M Mhashilkar; Sunil Chada; Rajagopal Ramesh
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.

Authors:  Serena Vannucchi; Maria V Chiantore; Gianna Fiorucci; Zulema A Percario; Stefano Leone; Elisabetta Affabris; Giovanna Romeo
Journal:  Oncogene       Date:  2005-04-07       Impact factor: 9.867

6.  Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.

Authors:  Sunil Chada; Abner M Mhashilkar; Rajagopal Ramesh; John B Mumm; R Bryan Sutton; Dora Bocangel; Mingzhong Zheng; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

7.  Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene.

Authors:  Yuji Saito; Ryo Miyahara; Began Gopalan; Anya Litvak; Satoshi Inoue; Manish Shanker; Cynthia D Branch; Abner M Mhashilkar; Jack A Roth; Sunil Chada; Rajagopal Ramesh
Journal:  Cancer Gene Ther       Date:  2005-03       Impact factor: 5.987

8.  Tumor iNOS predicts poor survival for stage III melanoma patients.

Authors:  Suhendan Ekmekcioglu; Julie A Ellerhorst; Victor G Prieto; Marcella M Johnson; Lyle D Broemeling; Elizabeth A Grimm
Journal:  Int J Cancer       Date:  2006-08-15       Impact factor: 7.396

9.  Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells.

Authors:  M I Darville; D L Eizirik
Journal:  Diabetologia       Date:  1998-09       Impact factor: 10.122

Review 10.  Interferon-beta gene therapy for cancer: basic research to clinical application.

Authors:  Jun Yoshida; Masaaki Mizuno; Toshihiko Wakabayashi
Journal:  Cancer Sci       Date:  2004-11       Impact factor: 6.716

View more
  13 in total

1.  Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma.

Authors:  Y A Bochkov; K M Hanson; S Keles; R A Brockman-Schneider; N N Jarjour; J E Gern
Journal:  Mucosal Immunol       Date:  2009-08-26       Impact factor: 7.313

2.  Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.

Authors:  Lisha Liu; Wen Qiu; Hui Wang; Yan Li; Jianbo Zhou; Mei Xia; Kai Shan; Rongrong Pang; Ying Zhou; Dan Zhao; Yingwei Wang
Journal:  J Biol Chem       Date:  2012-03-15       Impact factor: 5.157

3.  IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.

Authors:  Wu-Guo Deng; John Kwon; Suhendan Ekmekcioglu; Nancy J Poindexter; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

4.  Cell-Specific Requirements for STAT Proteins and Type I IFN Receptor Signaling Discretely Regulate IL-24 and IL-10 Expression in NK Cells and Macrophages.

Authors:  Djeneba Dabitao; Christian M Hedrich; Fengying Wang; Vimvara Vacharathit; Jay H Bream
Journal:  J Immunol       Date:  2018-02-07       Impact factor: 5.422

5.  (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma.

Authors:  Minakshi Nihal; Haseeb Ahsan; Imtiaz A Siddiqui; Hasan Mukhtar; Nihal Ahmad; Gary S Wood
Journal:  Cell Cycle       Date:  2009-07-27       Impact factor: 4.534

6.  MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation involved in cancer cell apoptosis.

Authors:  Hui Tian; Jing Wang; BaoFu Zhang; JieHui Di; FeiFei Chen; HuiZhong Li; LianTao Li; DongSheng Pei; JunNian Zheng
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

7.  Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.

Authors:  I M Germano; L Emdad; Z A Qadeer; E Binello; M Uzzaman
Journal:  Cancer Gene Ther       Date:  2010-06-04       Impact factor: 5.987

Review 8.  Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.

Authors:  Luni Emdad; Praveen Bhoopathi; Sarmistha Talukdar; Anjan K Pradhan; Devanand Sarkar; Xiang-Yang Wang; Swadesh K Das; Paul B Fisher
Journal:  Semin Cancer Biol       Date:  2019-07-26       Impact factor: 15.707

Review 9.  Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.

Authors:  Luni Emdad; Swadesh K Das; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

10.  Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.

Authors:  Cong-Jun Wang; Chao-Wen Xiao; Tian-Geng You; Ya-Xin Zheng; Wei Gao; Zhu-Qing Zhou; Jun Chen; Xin-Bo Xue; Jia Fan; Hui Zhang
Journal:  Mol Cancer       Date:  2012-05-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.